



Panacea Biotec

Innovation in support of life

May 24, 2021

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 531349

Re.: Press Release - Russian Direct Investment Fund and Panacea Biotec launch the production of Sputnik V in India

Dear Sir/Madam,

Panacea Biotec Ltd. is delighted to inform that the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, has today announced the launch of production of the Russian Sputnik V vaccine against coronavirus at Panacea Biotec's facilities at Baddi, Himachal Pradesh, India.

A copy of the Press Release titled “**RDIF and Panacea Biotec launch the production of Sputnik V in India**” being issued to the media, etc. in this regard is enclosed for your kind reference and record please.


Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**

Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl. As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Press release:

RDIF and Panacea Biotec launch the production of Sputnik V in India

Moscow/ New Delhi, May 24, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, today announced the launch of production of the Russian Sputnik V vaccine against coronavirus.

The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to start this summer. Company’s facilities comply with GMP standards and are prequalified by WHO.

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V.

To date Sputnik V has been registered in 66 countries globally with total population of over 3.2 billion people. Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Launch of production in India in partnership with Panacea Biotec marks an important step for helping the country fight the pandemic. Production of Sputnik V supports efforts of India’s authorities to leave behind the acute phase of coronavirus as soon as possible while the vaccine



will also be exported at a later stage to help prevent the spread of the virus in other countries around the world.”

Dr. Rajesh Jain, Managing Director, for Panacea Biotec, said:

“This marks a significant step as we initiate production of Sputnik V. Together with RDIF, we hope to help bring a sense of normalcy back to people across the country and around the world.”

Sputnik V has a number of key advantages:

- *Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;*
- *The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.*
- *Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.*
- *The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.*
- *There are no strong allergies caused by Sputnik V.*
- *The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.*
- *The price of Sputnik V is less than \$10 per shot, making it affordable around the world.*

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from



more than 18 countries that total more than \$40 bn. Further information can be found at www.rdif.ru

For additional information contact:

<p>Alexey Urazov <i>Russian Direct Investment Fund</i> Director for External Communications Mobile: +7 915 312 76 65 Tel: +44 (0) 20 7796 4133</p>	<p>Andrew Leach / Maria Shiryaevskaya Hudson Sandler E-mail: Alexey.Urazov@rdif.ru</p>
--	--

Panacea Biotec is an innovation-led biopharmaceutical group that focuses on discovery, development, and commercialization of prescription medicines primarily, focusing on Vaccines, Diabetes, Transplant, Gastroenterology, and Oncology. Panacea Biotec launched the world's first fully-liquid Hexavalent vaccine (DTwP-Hib-HepB-IPV), EasySix in 2017. Company is also developing a Dengue Vaccine, Pneumococcal Conjugate vaccine among other differentiated drug development programs. Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs while ensuring affordability. For more information, visit: www.panaceabiotec.com

For additional information contact:

For Investors:	For Media:
<p>Mr. Devender Gupta Chief Financial Officer and Head Information Technology Tel: + 91-11-41679000 Ext. 1225, 41578011 (Direct) Email: devendergupta@panaceabiotec.com</p>	<p>Mr. PD. Karan Vice President Corporate Communication & Business Development Tel: + 91-11-4167900 Ext.1406 41578080 (Direct) Email: pdkaran@panaceabiotec.com</p>